Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease

Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease
复制标题

DOI:
10.1038/ki.2009.503
复制
发表时间:
2010-03-01
影响因子:
19.6
通讯作者:
Massy, Ziad A.
Massy, Ziad A.
中科院分区:
医学1区
文献类型:
--
作者:
Barreto, Daniela V.;Barreto, Fellype C.;Massy, Ziad A.

文献摘要

被引文献

相似文献

与慢性肾脏疾病相关的慢性炎症预测血液透析患者的全因死亡率和心血管死亡率。在这里,我们试图评估125例慢性肾病不同阶段(2-5D)患者血浆炎症介质白细胞介素-6 (IL-6)水平与死亡率和主动脉钙化/僵硬之间的关系。通过多元线性回归,我们发现血浆IL-6与c反应蛋白、白蛋白和慢性肾病分期独立相关,但与主动脉钙化评分或脉搏波速度无关。在随访研究期间(中位数为829天),38例患者死亡,22例死于心血管事件。血浆IL-6可显著预测总体死亡率和心血管死亡率;在多次调整或限制透析前患者的分析后,这种关联仍然存在。此外,IL-6比c反应蛋白、白蛋白或肿瘤坏死因子-a更能预测死亡率。因此,血浆IL-6独立预测慢性肾病不同阶段患者的总体死亡率和心血管死亡率;然而,降低血浆IL-6是否会影响慢性肾脏疾病的预后还需要更直接的评估。肾脏国际(2010)77,550-556;doi: 10.1038 / ki.2009.503;2009年12月16日在线发布
Chronic inflammation associated with chronic kidney disease predicts all-cause and cardiovascular mortality in hemodialysis patients. Here we sought to evaluate the association between plasma levels of the inflammatory mediator interleukin-6 (IL-6) and mortality and aortic calcification/stiffness in 125 patients at different stages (2-5D) of chronic kidney disease. Using multivariate linear regression, we found that plasma IL-6 was independently associated with C-reactive protein, albumin and the stage of chronic kidney disease, but not the aortic calcification score or pulse wave velocity. During follow-up studies (median of 829 days), 38 patients died, 22 from cardiovascular events. Plasma IL-6 significantly predicted overall and cardiovascular mortality; this association persisted after multiple adjustments or restricting the analysis to pre-dialysis patients. Moreover, IL-6 was a significantly better predictor of mortality than C-reactive protein, albumin or tumor necrosis factor-a. Hence, plasma IL-6 independently predicted overall and cardiovascular mortality in patients at different stages of chronic kidney disease; however, whether lowering plasma IL-6 will affect the outcome of chronic kidney disease will require more direct evaluation. Kidney International (2010) 77, 550-556; doi: 10.1038/ki.2009.503; published online 16 December 2009